Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Symphogen

Request full access

Develops antibodies for cancer treatments

Ballerup, DenmarkFounded 2000Biotech & Life Sciences

About Symphogen

Symphogen was founded in 2000 by Kirsten Drejer, a visionary in the field of biotechnology. The company, based in Ballerup, Denmark, set out with a mission to develop innovative recombinant antibody therapies aimed at treating cancer and other serious diseases. Symphogen's approach was unique, focusing on creating mixtures of monoclonal antibodies to enhance treatment efficacy and patient outcomes.

Over the years, Symphogen made significant strides in the biopharmaceutical industry, advancing its pipeline of antibody therapies through rigorous research and development. The company's dedication to innovation and patient care positioned it as a leader in the field of oncology-focused antibody treatments.

A pivotal moment in Symphogen's journey came in June 2020, when it became part of the Servier Group, a global pharmaceutical company. This acquisition was a strategic move to bolster Servier's oncology research and development capabilities, aligning with their commitment to improving patient health worldwide. The integration into Servier provided Symphogen with additional resources and support to further its mission of developing cutting-edge therapies.

Today, Symphogen continues to operate as a key player within the Servier Group, driving forward its research in antibody therapies. The company's story is one of innovation, resilience, and a steadfast commitment to transforming the landscape of cancer treatment through scientific excellence.

Source: Dealroom company data

Symphogen in the Ballerup ecosystem

Live from Dealroom

The Symphogen office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Madison Alley Global Ventures

Series B and later5 investors entered at this stage

  • Essex Woodlands Health Ventures
  • Novo Holdings
  • Gilde Healthcare
  • Takeda Ventures
  • EW Healthcare Partners
Employees mapped 214 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 33 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Symphogen on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.